Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions….
RVV.C
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin….
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the…
The ongoing COVID-19 drama that’s dragged markets to its knees may almost be over, as finally companies have made some headway and there’s a drug out there that’s been…
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)…
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming…
The long and short of it is that psychedelics aren’t here yet. There are plenty of companies in various stages of development, doing what they can to make various…
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space…
Revive Therapeutics (RVV.C) intends to advance its product pipeline to human clinical studies in regions where its products have already acquired regulatory approval and are approved for sale. The…
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business….